Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Management Statement

6 Nov 2009 07:00

RNS Number : 0801C
Stanelco PLC
06 November 2009
 



6 November 2009

Stanelco plc ("the Company" or "the Group")

Interim Management Statement

Stanelco plc issues its interim management statement for the period from 1 January 2009 to 5 November 2009, as required by the UK Listing Authority's Disclosure and Transparency Rules.

Highlights

Sales to 30 September up 12% to £13.4m

Trading performance in line with Board's expectations:

Continued growth in bioplastics division driven by interest in adopting sustainable products; increasing applications in new sectors

Radio frequency applications division sales order pipeline continued to strengthen; growing overseas sales in China and India

Closing cash position at 30 September £3.7m, increased by working capital improvements

Board confident in full year outlook

Trading Update

Group revenues grew strongly during the nine months to 30 September 2009 and the Group's overall trading performance was in line with the Board's expectations.

Group revenues increased from £12.0m to £13.4m in the nine months to 30 September 2009, an increase of 12% compared with the same period last year. This reflected a 29% increase in bioplastic sales made directly by the Company, a 30% increase in sales in RF Applications division and an 8% increase in third party sales from our joint venture, Biotec.

Our cash position at 30 September 2009 was £3.7m, strengthened since the half year by working capital improvements, including a reduction in stock levels following the summer production holiday.

Bioplastics division

In the Bioplastics division, the sales team that was established last year has had a number of successes in growing sales of the Group's existing biodegradable products into the market, delivering a 29% increase in the Company's bioplastic sales in the nine months to 30 September 2009. The division has broadened its customer base with over 40 new customers in 2009 and widened the set of end-use applications by a further 17 in the same period. The management remain encouraged by the division's opportunities for growth.

The product development team continues to work closely with a number of blue chip customers and mainstream plastics convertors to develop a widening range of biodegradable products that can substitute oil-based plastics. Whilst some of these development paths are still at an early stage, others are poised to deliver further growth in the coming months. The development team continues to focus on those accounts which we consider could have the maximum growth potential.

We continue to see strong demand for bioplastic products in the market, driven not only by concerns about waste disposal but also by the desire of many large corporations to switch to using sustainable resources in key brandsThis switch to the use of "renewable" materials in advance of legislation is seen as both a branding enhancement and a hedge against further oil based price rises.   Sectors in which we are gaining traction include packaging, waste disposal, paper products, personal care, horticulture and electronics. The sales development work undertaken in the USA over the past year is now also gaining momentum. 

Our joint venture, Biotec, delivered 8% growth in its third party sales for the 9 months to 30 September 2009  compared with the same period last year.

Radio Frequency (RF) applications division 

In the RF Applications division, the team has been fulfilling a number of significant orders that have been won in the nine months to 30 September 2009, including the £0.3m order for RF furnaces disclosed in our interim results. Sales in the period increased by 30% compared with the same period last year including growth in both optical fibre furnaces and more general industrial equipment in which we are building a portfolio of customers making repeat orders.  The sales order pipeline continues to strengthen with a particular emphasis on sales in India and China. As a result, a new sales consultant has now been appointed for Stanelco dedicated to the Indian market, as this territory shows signs of increasing growth in the next few years.

Outlook

The Board continues to be confident in the outlook for the full year. Our focus continues to be on working closely with customers with the potential to deliver increases in revenue, whilst considering acquisition opportunities and other paths that could significantly increase the scale of the business and deliver shareholder value. 

- Ends -

For further information please contact:

Paul Mines, Chief Executive, Stanelco plc

Sue Bygrave, Group Finance Director, Stanelco plc

Tel: +44 (0) 2380 867100

Jonathon Brill/Caroline Stewart

Financial Dynamics

Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBABRTMMJMBFL
Date   Source Headline
21st Mar 20257:00 amRNSCancellation- Biome Technologies PLC
13th Mar 202512:22 pmRNSResult of GM & update on Cancellation
21st Feb 20257:00 amRNSProposed Cancellation & Notice of GM
18th Dec 20247:00 amRNSSecured Funding Facility
4th Dec 20247:00 amRNSTrading Update and Board Change
13th Nov 20247:00 amRNSTrading Update
25th Oct 20247:00 amRNSAppointment of Non-Executive Director
30th Sep 20245:00 pmRNSTotal Voting Rights
30th Sep 202411:08 amRNSContract win for Stanelco RF Division
20th Sep 20247:00 amRNSInterim Results
13th Sep 202410:58 amRNSHolding(s) in Company
12th Sep 202411:43 amRNSHolding(s) in Company
11th Sep 20243:01 pmRNSHolding(s) in Company
10th Sep 20247:00 amRNSHolding(s) in Company
9th Sep 20244:51 pmRNSHolding(s) in Company
4th Sep 20242:39 pmRNSResult of General Meeting and TVR
30th Aug 20245:00 pmRNSTotal Voting Rights
23rd Aug 20242:42 pmRNSHolding(s) in Company
22nd Aug 202411:00 amRNSHolding(s) in Company
22nd Aug 20247:00 amRNSResult of Retail Offer, Director dealing and TVR
21st Aug 20244:12 pmRNSHolding(s) in Company
21st Aug 20241:41 pmRNSHolding(s) in Company
16th Aug 20247:05 amRNSRetail offer to raise up to £80,000
16th Aug 20247:01 amRNSProposed Fundraise and other matters
16th Aug 20247:00 amRNSTrading update
10th Jul 20247:00 amRNSDirectorate Change
8th Jul 20247:00 amRNSTrading update
12th Jun 20247:00 amRNSGrant of Options
29th May 202410:57 amRNSResult of AGM, Interim CFO and Directorate Change
22nd May 20242:27 pmRNSContract win for Stanelco RF Division
15th May 20247:00 amRNSNotice of AGM and 2023 Annual Report
29th Apr 20247:01 amRNSTrading Update
29th Apr 20247:00 amRNSFinal Results 2023
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.